The Swiss pharmaceutical company Roche has tightened its sales forecast for the entire year. The company did so after strong sales of newer medicines in the third quarter. The outlook for the pipeline of new products is also positive, the company said.
Roche is now counting on revenue growth of around 9 percent. Previously a bandwidth of approximately 5 to 9 percent was mentioned. The result is also likely to rise to the same extent, Roche thinks.
The company achieved sales of 46.1 billion Swiss francs in the first nine months of the year.
Abaigael Schlomski is an accomplished economist and financial journalist with over a decade of experience in the industry. He is a regular contributor to EconomicInform, where he provides in-depth analysis and expert commentary on the latest economic trends and events. With a keen understanding of the financial markets and a talent for breaking down complex economic concepts for a general audience, Maurice is a trusted and respected voice in the field.
